Table 1.
Baseline characteristics according to the presence or absence of SVT after the last RFCA procedure.
| All | Long-term SVT (n = 12) | No long-term SVT (n = 11) | p value | |
|---|---|---|---|---|
| Age, years | 47 (35–60) | 44 (35–56) | 51 (35–66) | 0.22 |
| Female sex | 15 (65%) | 8 (67%) | 7 (64%) | 1.00 |
| PAH | 19 (83%) | 12 (100%) | 7 (64%) | 0.0373 |
| CHD | 13 (57%) | 8 (67%) | 5 (45%) | 0.30 |
| CTEPH | 3 (13%) | 0 (0%) | 3 (27%) | 0.093 |
| CRF with dialysis | 1 (4%) | 0 (0%) | 1 (9%) | 0.48 |
| Intravenous PGI2 | 8 (35%) | 5 (42%) | 3 (27%) | 0.67 |
| Number of AADs | 1 (0–2) | 2 (0.3–2.8) | 1 (0–2) | 0.22 |
| BNP level, pg/mL | 178 (60–254) | 156 (97–397) | 218 (54–253) | 0.70 |
| Hospitalizations before RFCA, times/year | 1 (0–1) | 1 (0–1) | 0 (0–1) | 0.19 |
| Right heart catheterization | ||||
| Mean PAP, mmHg | 44 (32–50) | 43 (34–50) | 44 (28–48) | 0.67 |
| RAP, mmHg | 8 (5–13) | 10 (8–19) | 6 (3–11) | 0.14 |
| CO, L/min | 3.8 (2.4–4.4) | 2.7 (2.2–4.2) | 4.3 (2.8–4.8) | 0.19 |
| CI, L/min/m2 | 2.5 (1.6–3.1) | 1.7 (1.6–2.9) | 2.7 (2.0–3.2) | 0.42 |
| SvO2, % | 67 (57–80) | 68 (63–78) | 63 (42–69) | 0.18 |
| PCWP, mmHg | 9 (6–15) | 11 (7–18) | 9 (4–12) | 0.28 |
| PVR, dyne·sec/cm5 | 733 (628–1204) | 987 (696–1364) | 650 (521–1049) | 0.14 |
| RFCA | ||||
| AFL | 18 (78%) | 11 (92%) | 7 (64%) | 0.16 |
| AT* | 8 (48%) | 4 (33%) | 4 (36%) | 1.00 |
| AVNRT | 1 (4%) | 0 (0%) | 1 (9%) | 0.48 |
AAD antiarrhythmic drug, AF: atrial fibrillation, AFL: common atrial flutter, AT: atrial tachycardia, AVNRT: atrioventricular nodal reentrant tachycardia, BNP: brain natriuretic peptide, CHD: congenital heart disease, CI: cardiac index, CO: cardiac output, CRF: chronic renal failure, CTEPH: chronic thromboembolic pulmonary hypertension, PAH: pulmonary arterial hypertension, PAP: pulmonary artery pressure, PCWP: pulmonary capillary wedge pressure, PG: prostaglandin, PVR: pulmonary vascular resistance, RAP: right atrium pressure, RFCA: radiofrequency catheter ablation, SvO2: mixed venous oxygen saturation, SVT: supraventricular tachycardia.
*AT did not include non-sustained AT in this table.